EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Oncogenic Signalling Pathways in Cancer Immunotherapy: Leader or Follower in This Delicate Dance?

Douglas Cartwright, Andrew C Kidd, Sonam Ansel, Maria Libera Ascierto, Pavlina Spiliopoulou iD

International Journal of Molecular Sciences · 06.05.2025 · 26 (9) · 4393

DOI: 10.3390/ijms26094393 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.05.2025. Verfasst von Douglas Cartwright und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Cancer Sciences, University of Glasgow, Bearsden, Glasgow G61 1QH, UK. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Signal Transduction, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors have become a mainstay of treatment in many solid organ malignancies. Alongside this has been the rapid development in the identification and targeting of oncogenic drivers. The presence of alterations in oncogenic drivers not only predicts response to target therapy but can modulate the immune microenvironment and influence response to immunotherapy. Combining immune checkpoint inhibitors with targeted agents is an attractive therapeutic option but overlapping toxicity profiles may limit the clinical use of some combinations. In addition, there is growing evidence of shared resistance mechanisms that alter the response to immunotherapy when it is used after targeted therapy. Understanding this complex interaction between oncogenic drivers, targeted therapy and response to immune checkpoint inhibitors is vital for selecting the right treatment, at the right time for the right patient. In this review, we summarise the preclinical and clinical evidence of the influence of four common oncogenic alterations on immune checkpoint inhibitor response, combination therapies, and the presence of shared resistance mechanisms. We highlight the common resistance mechanisms and the need for more randomised trials investigating both combination and sequential therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapySignal TransductionImmune Checkpoint InhibitorsHumansTumor MicroenvironmentAnimalsDrug Resistance, NeoplasmMolecular Targeted Therapy

Stichwörter der Autor:innen

immunotherapyoncogenic driversresistance mechanismstargeted therapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • School of Cancer Sciences, University of Glasgow, Bearsden, Glasgow G61 1QH, UK.
  • Beatson West of Scotland Cancer Centre,1053 Great Western Road, Glasgow G12 0YN, UK.

ORCID-Profile: Pavlina Spiliopoulou

Zitieren

APA

Cartwright, D., Kidd, A. C., Ansel, S., Ascierto, M. L., & Spiliopoulou, P. (2025). Oncogenic Signalling Pathways in Cancer Immunotherapy: Leader or Follower in This Delicate Dance?. International Journal of Molecular Sciences, 26(9), 4393. https://doi.org/10.3390/ijms26094393

Vancouver

Cartwright D, Kidd AC, Ansel S, Ascierto ML, Spiliopoulou P. Oncogenic Signalling Pathways in Cancer Immunotherapy: Leader or Follower in This Delicate Dance?. International Journal of Molecular Sciences. 2025;26(9):4393. doi:10.3390/ijms26094393

BibTeX
@article{Cartwright2025,
  author = {Cartwright, Douglas and Kidd, Andrew C and Ansel, Sonam and Ascierto, Maria Libera and Spiliopoulou, Pavlina},
  title = {Oncogenic Signalling Pathways in Cancer Immunotherapy: Leader or Follower in This Delicate Dance?},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {9},
  pages = {4393},
  doi = {10.3390/ijms26094393}
}
Kostenlos starten →